Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deal Watch: Vertex Selects First Candidate Under CRISPR Gene-Editing Collaboration

Executive Summary

Vertex hopes to develop CTX001 as a treatment for sickle cell disease and beta thalassemia. Allergan adds stalled uterine fibroid candidate in buyout of troubled Repros, Juno licenses multiple myeloma candidate from Lilly.


Related Content

CRISPR Therapeutics, Vertex Initiate First Industry-Sponsored Trial – What’s Next?
US FDA Tweaks IND Clinical Hold Policy As Number Of Holds Rises
The Next Challenge: Improving And Predicting Responses As CAR-T Therapies Advance
Gilead Acquisition Of Cell Design: The Next Logical Step
Hisun-Pfizer Split: What Went Wrong And What Next?
Synlogic Moves Synthetic Biotics To The Clinic For Rare Metabolic Disease
Takeda Paves The Way For Myovant With Phase III Fibroid Success
Arena Rises, But Raises Questions With Phase II Ralinepag Data In PAH
Deal Watch: Taking Care Of Business Before J.P. Morgan
Cannabis Derivative Sativex 'Shows Promise In US Patients' Despite Further Phase III Failure


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts